Pages that link to "Q29615809"

The following pages link to Targeting the phosphoinositide 3-kinase pathway in cancer (Q29615809):

Displaying 50 items.

• Akt and mTOR in B Cell Activation and Differentiation (Q21131224) (← links)
• Second AKT: the rise of SGK in cancer signalling (Q24301817) (← links)
• Interactome mapping of the phosphatidylinositol 3-kinase-mammalian target of rapamycin pathway identifies deformed epidermal autoregulatory factor-1 as a new glycogen synthase kinase-3 interactor (Q24305619) (← links)
• Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions (Q24339544) (← links)
• The Skp2-SCF E3 ligase regulates Akt ubiquitination, glycolysis, herceptin sensitivity, and tumorigenesis (Q24613186) (← links)
• Targeting mTOR for the treatment of AML. New agents and new directions (Q24617223) (← links)
• Emerging role of Lys-63 ubiquitination in protein kinase and phosphatase activation and cancer development (Q24622802) (← links)
• Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy (Q24628724) (← links)
• Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy (Q24632296) (← links)
• Regulation of mRNA export by the PI3 kinase/AKT signal transduction pathway (Q24634371) (← links)
• Identification and functional characterization of paxillin as a target of protein tyrosine phosphatase receptor T (Q24646348) (← links)
• Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab (Q26764879) (← links)
• Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics (Q26766292) (← links)
• PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma (Q26766293) (← links)
• The PI3K/Akt Pathway in Tumors of Endocrine Tissues (Q26770404) (← links)
• DAB2IP in cancer (Q26776456) (← links)
• Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer (Q26778349) (← links)
• The use of dynamic nuclear polarization (13)C-pyruvate MRS in cancer (Q26778444) (← links)
• miRNA interventions serve as 'magic bullets' in the reversal of glioblastoma hallmarks (Q26781836) (← links)
• The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients (Q26782449) (← links)
• The Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive Life (Q26785614) (← links)
• Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer (Q26795625) (← links)
• Current medical treatment of estrogen receptor-positive breast cancer (Q26795751) (← links)
• The Role of the PI3K Pathway in the Regeneration of the Damaged Brain by Neural Stem Cells after Cerebral Infarction (Q26796283) (← links)
• Cancer cells exploit adaptive mitochondrial dynamics to increase tumor cell invasion (Q26796364) (← links)
• Focus on PTEN Regulation (Q26797287) (← links)
• p38 MAPK and PI3K/AKT Signalling Cascades inParkinson's Disease (Q26799375) (← links)
• Harnessing the apoptotic programs in cancer stem-like cells (Q26801037) (← links)
• New molecular targets in mantle cell lymphoma (Q26821766) (← links)
• miR-128 and its target genes in tumorigenesis and metastasis (Q26824791) (← links)
• The role of obesity in gastrointestinal cancer: evidence and opinion (Q26825678) (← links)
• Emerging targeted therapies for melanoma treatment (review) (Q26829997) (← links)
• The Akt-associated microRNAs (Q26830734) (← links)
• PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms (Q26862544) (← links)
• Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer (Q27001260) (← links)
• PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer (Q27006181) (← links)
• Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications (Q27009016) (← links)
• Anti-inflammatory/antioxidant use in long-term maintenance cancer therapy: a new therapeutic approach to disease progression and recurrence (Q27010314) (← links)
• Phosphoinositides: tiny lipids with giant impact on cell regulation (Q27012953) (← links)
• Posttranslational regulation of Akt in human cancer (Q27027815) (← links)
• Crystal Structure of Human AKT1 with an Allosteric Inhibitor Reveals a New Mode of Kinase Inhibition (Q27664839) (← links)
• Identification and structure–activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors (Q27665439) (← links)
• The p110α and p110β isoforms of PI3K play divergent roles in mammary gland development and tumorigenesis (Q27851848) (← links)
• First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors (Q27853088) (← links)
• Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents (Q28067417) (← links)
• The therapeutic potential of targeting the PI3K pathway in pediatric brain tumors (Q28070264) (← links)
• Molecular predictive markers in tumors of the gastrointestinal tract (Q28070583) (← links)
• The Anticancer Properties of Herba Epimedii and Its Main Bioactive Componentsicariin and Icariside II (Q28070895) (← links)
• Maximising the potential of AKT inhibitors as anti-cancer treatments (Q28072254) (← links)
• Developmental therapeutics for inflammatory breast cancer: Biology and translational directions (Q28075322) (← links)